Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

161. Accu-Chek Insight insulin pump system, manufactured by Roche Diabetes Care ? risk of inappropriate treatment

Accu-Chek Insight insulin pump system, manufactured by Roche Diabetes Care ? risk of inappropriate treatment Accu-Chek® Insight insulin pump system, manufactured by Roche Diabetes Care – risk of inappropriate treatment - GOV.UK GOV.UK uses cookies to make the site simpler. Search Accu-Chek® Insight insulin pump system, manufactured by Roche Diabetes Care – risk of inappropriate treatment From: Published: 12 May 2016 Last updated: 12 May 2016, Issued: 12 May 2016 Alert type: Medical specialism (...) : Risk of a hypoglycaemic event if users misinterpret maintenance message ‘M-83 pump not able to complete task’. Users are advised to check pump history before re-initiating a programmed task (e.g. bolus delivery) MDA/2016/005. Contents Action Identify users of the Accu-Chek® Insight insulin pump system. Ensure that all patients and users receive the manufacturer’s Field Safety Notice and that they understand the problem and the advice given by the manufacturer. Include a copy of the FSN

MHRA Drug Safety Update2016

162. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes 26435365 2016 03 21 2016 12 23 2017 02 20 1464-5491 33 4 2016 Apr Diabetic medicine : a journal of the British Diabetic Association Diabet. Med. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared (...) with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes. 497-505 10.1111/dme.12982 To evaluate the efficacy and safety of twice-daily insulin degludec/insulin aspart vs. twice-daily biphasic insulin aspart 30 in people with Type 2 diabetes mellitus who were naïve to insulin. In this 26-week, multinational, open-label, controlled, two-arm, parallel-group, treat-to-target trial, participants [mean (± sd) age 58.9 (±8.9) years, duration of diabetes 9.5 (±5.9) years, HbA1c 68 (±8.7

EvidenceUpdates2016

163. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1) 26662964 2016 03 13 2016 12 19 2017 02 20 1463-1326 18 4 2016 Apr Diabetes, obesity & metabolism Diabetes Obes Metab New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a (...) randomized controlled trial (EDITION JP 1). 375-83 10.1111/dom.12619 To compare efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of insulin glargine 100 U/ml (Gla-100) in Japanese adults with type 1 diabetes. The EDITION JP 1 study (NCT01689129) was a 6-month, multicentre, open-label, phase III study. Participants (n = 243) were randomized to Gla-300 or Gla-100 while continuing mealtime insulin. Basal insulin was titrated with the aim of achieving a fasting self-monitored plasma

EvidenceUpdates2016

164. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. 26934259 2016 03 03 2016 03 08 2016 10 17 1538-3598 315 9 2016 Mar 01 JAMA JAMA Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. 898-907 10.1001/jama.2016.1252 Achieving (...) glycemic control remains a challenge for patients with type 2 diabetes, even with insulin therapy. To assess whether a fixed ratio of insulin degludec/liraglutide was noninferior to continued titration of insulin glargine in patients with uncontrolled type 2 diabetes treated with insulin glargine and metformin. Phase 3, multinational, multicenter, 26-week, randomized, open-label, 2-group, treat-to-target trial conducted at 75 centers in 10 countries from September 2013 to November 2014 among 557

JAMA2016

166. Insulin detemir (Levemir) - for treatment of diabetes mellitus

Insulin detemir (Levemir) - for treatment of diabetes mellitus Published 07 March 2016 Product Update: insulin detemir 100units/mL, solution for injection in cartridge (Penfill), pre- filled pen (FlexPen) and pre-filled pen (InnoLet) (Levemir ® ) Novo Nordisk Limited SMC No. (1126/16) 05 February 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission insulin detemir (Levemir ® ) is accepted for restricted use within NHS Scotland. Indication under review: for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. SMC restriction: in patients unable to achieve good glycaemic control with established insulins. Insulin detemir has previously been accepted for restricted use by SMC in adults, adolescents and children from 2 years of age

Scottish Medicines Consortium2016

167. Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus.

Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus. 26909482 2016 02 25 2016 09 27 2016 02 25 2359-4292 60 1 2016 Feb Archives of endocrinology and metabolism Arch Endocrinol Metab Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus. 47-53 10.1590/2359-3997000000140 S2359-39972016000100047 To compare the effects of the neutral protamine Hagedorn (NPH (...) ) recombinant human insulin formulations Gansulin and Humulin N® on the glycemic control of patients with type 2 diabetes mellitus (T2DM). Prospective, double-blind, randomized, parallel, single-center study of 37 individuals with T2DM treated with NPH insulin formulations. The Tukey-Kramer test for multiple comparisons, the Wilcoxon paired comparison test and the Chi-Square test were used for the statistical analyses. The significance level was set at 5% (p < 0.05). The NPH insulin formulations Humulin

Archives of endocrinology and metabolism2016

168. Insulin Resistance and a Long, Strange Trip.

Insulin Resistance and a Long, Strange Trip. Insulin Resistance and a Long, Strange Trip. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26886417 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Apr 7;374(14):1378-9. doi: 10.1056/NEJMe1600962. Epub 2016 Feb 17. Insulin Resistance and a Long, Strange Trip. 1 . 1 From the Division of Endocrinology, Metabolism and Lipid Research, Washington University, St. Louis. Comment on [N Engl J Med. 2016] PMID: 26886417 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full

NEJM2016

169. Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines

Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines | CADTH.ca Find the information you need Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness (...) and Guidelines Published on: December 10, 2015 Project Number: RC0731-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of insulin pumps versus multiple daily injections for adults with type 1 diabetes? What is the comparative clinical effectiveness of insulin pump models with continuous glucose monitors versus standard insulin pumps for adults with type 1 diabetes? What is the cost-effectiveness

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

170. Insulin therapy in type 1 diabetes

Insulin therapy in type 1 diabetes Insulin therapy in type 1 diabetes - NICE CKS Clinical Knowledge Summaries Share Insulin therapy in type 1 diabetes: Summary Insulin is a polypeptide hormone secreted by pancreatic beta-cells. The role of insulin is to lower blood glucose to prevent hyperglycaemia and its associated complications, including microvascular complications (retinopathy, nephropathy, and neuropathy), macrovascular complications (cardiovascular, cerebrovascular, and peripheral (...) arterial disease), and metabolic complications (diabetic ketoacidosis and dyslipidaemia). In people with type 1 diabetes, autoimmune destruction of pancreatic beta-cells results in absolute insulin deficiency. Consequently, insulin therapy is a medical necessity. Three types of insulin are available in the UK: human insulins, human insulin analogues, and animal insulins (rarely used). Insulins are broadly categorized according to their time-action profiles as: Short-acting insulins — these are used

NICE Clinical Knowledge Summaries2016

171. Randomised controlled trial: Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes

Randomised controlled trial: Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes Article Text Therapeutics/Prevention Randomised controlled trial Blood glucose monitoring had no impact on distress or self

Evidence-Based Medicine (Requires free registration)2016

172. Insulin therapy in type 2 diabetes

Insulin therapy in type 2 diabetes Insulin therapy in type 2 diabetes - NICE CKS Clinical Knowledge Summaries Share Summary: Insulin therapy in type 2 diabetes Insulin is a polypeptide hormone secreted by pancreatic beta-cells. The role of insulin is to lower blood glucose to prevent hyperglycaemia and its associated complications, including microvascular complications (retinopathy, nephropathy, and neuropathy), macrovascular complications (cardiovascular, cerebrovascular, and peripheral (...) arterial disease), and metabolic complications (dyslipidaemia and diabetic ketoacidosis). In people with type 2 diabetes, there is a variable combination of increased insulin resistance and progressive loss of pancreatic beta-cell function. Type 2 diabetes is initially managed with lifestyle changes and antidiabetic drugs. However, with time, many people will require insulin therapy as there is insufficient endogenous insulin to maintain adequate glucose control. Three types of insulin are available

NICE Clinical Knowledge Summaries2016

173. Subcutaneous Insulin in the Treatment of Diabetic Ketoacidosis in the Pediatric Population

Subcutaneous Insulin in the Treatment of Diabetic Ketoacidosis in the Pediatric Population "Subcutaneous Insulin in the Treatment of Diabetic Ketoacidosis in the " by Lauren A. Ljunghag < > > > > > Title Author Date of Award Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Diabetic ketoacidosis or DKA is an acute and fatal disease that is highly prevalent in the pediatric population. The current gold (...) standard of treatment is continuous intravenous regular insulin (CIRI), which requires admission to the intensive care unit (ICU) and is a substantial cost to the patient. Alternate routes of insulin administration, such as subcutaneous (SQ) insulin, do not require ICU admission. If SQ insulin is found to be safe and efficacious for the treatment of DKA, this treatment modality could replace continuous IV regular insulin, and therefore decrease the need for ICU admission and cost of stay. Methods

Pacific University EBM Capstone Project2016

175. BPG for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes

BPG for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes BPG for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes | Registered Nurses' Association of Ontario l’Association des infirmières et infirmiers autorisés de l’Ontario Speaking out for nursing. Speaking out for health. » » BPG for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes Type of Guideline: Clinical Status: Published Publish Date: 2004 About this Guideline (...) : The focus of this guideline is to support nurses in all practice settings, as they care for clients (18 years and older) with type 2 diabetes requiring subcutaneous insulin therapy. Specifically, this guideline would assist nurses who are not specialists in diabetes care to safely initiate and administer insulin, a “high-alert” medication. This guideline will provide answers to the question: What are the essential client self-care components to be addressed by nurses when caring for an adult

Registered Nurses' Association of Ontario2016

176. Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus

Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Article Text Therapeutics/Prevention Randomized clinical trial Detemir is non-inferior to NPH insulin in women

Evidence-Based Medicine (Requires free registration)2016

177. [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)]

[Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 316. 2015 Final publication URL Indexing Status Subject

Health Technology Assessment (HTA) Database.2016

178. [Insulin degludec (addendum to Commission A15-10)]

[Insulin degludec (addendum to Commission A15-10)] Insulin degludec (addendum zum Auftrag A15-10) [Insulin degludec (addendum to Commission A15-10)] Insulin degludec (addendum zum Auftrag A15-10) [Insulin degludec (addendum to Commission A15-10)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec (addendum zum (...) Auftrag A15-10). [Insulin degludec (addendum to Commission A15-10)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 315. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Hypoglycemic Agents; Insulin, Long-Acting Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel

Health Technology Assessment (HTA) Database.2016

179. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V]

[Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment (...) according to §35a Social Code Book V] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und

Health Technology Assessment (HTA) Database.2016

180. [Insulin degludec/liraglutide (Addendum to Commission A15-15)]

[Insulin degludec/liraglutide (Addendum to Commission A15-15)] Insulin degludec/liraglutid (addendum zum Auftrag A15-15) [Insulin degludec/liraglutide (Addendum to Commission A15-15)] Insulin degludec/liraglutid (addendum zum Auftrag A15-15) [Insulin degludec/liraglutide (Addendum to Commission A15-15)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation IQWiG. Insulin degludec/liraglutid (addendum zum Auftrag A15-15). [Insulin degludec/liraglutide (Addendum to Commission A15-15)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 327. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Hypoglycemic Agents; Insulin, Long-Acting Language Published German Country of organisation Germany English summary There is no English language summary available

Health Technology Assessment (HTA) Database.2016